January 11, 2016.
Shire announced today that it has entered into an agreement to acquire Baxalta under a cash and stock deal valued at $45.57 per share, or approximately $32 billion.
The combination of Baxalta and Shire would reportedly create "the number-one rare diseases platform in revenue and pipeline depth", with best-in-class products in each of the following franchises: hematology, immunology, neuroscience, lysosomal storage diseases, gastrointestinal/endocrine, and hereditary angioedema (HAE).
Shire CEO Flemming Ornskov said that the expanded portfolio "will drive our growth to over $20 billion in anticipated annual revenues by 2020."
Can Data and AI Deliver Whole-Person Health?
July 9th 2024Executives in the life sciences and medical device industries see promise in artificial intelligence (AI) and medical technologies, but must also navigate the changing healthcare ecosystem, varied stakeholder needs, and the impact of AI on market access and commercialization strategies.